Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX21
|
| gptkbp:brand |
gptkb:Gavreto
|
| gptkbp:CASNumber |
2097132-83-2
|
| gptkbp:chemicalFormula |
C27H32N6O3
|
| gptkbp:developer |
gptkb:Roche
gptkb:Blueprint_Medicines |
| gptkbp:form |
capsule
|
| gptkbp:genericName |
gptkb:pralsetinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gavreto
|
| gptkbp:indication |
gptkb:RET_fusion-positive_cancers
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:mechanismOfAction |
RET kinase inhibitor
|
| gptkbp:molecularWeight |
488.58 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
constipation fatigue hypertension increased liver enzymes |
| gptkbp:target |
gptkb:RET_proto-oncogene
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:RET_fusion-positive_thyroid_cancer |
| gptkbp:bfsParent |
gptkb:pralsetinib
|
| gptkbp:bfsLayer |
6
|